We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Amphastar Pharmaceuticals (AMPH - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amphastar Pharmaceuticals is a member of our Medical group, which includes 1139 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Amphastar Pharmaceuticals is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AMPH's full-year earnings has moved 22.4% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, AMPH has returned 108.4% so far this year. Meanwhile, stocks in the Medical group have lost about 1.2% on average. This shows that Amphastar Pharmaceuticals is outperforming its peers so far this year.
Another stock in the Medical sector, Arbutus Biopharma (ABUS - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 6%.
For Arbutus Biopharma, the consensus EPS estimate for the current year has increased 22.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amphastar Pharmaceuticals belongs to the Medical - Generic Drugs industry, a group that includes 17 individual stocks and currently sits at #79 in the Zacks Industry Rank. On average, stocks in this group have gained 8.8% this year, meaning that AMPH is performing better in terms of year-to-date returns.
On the other hand, Arbutus Biopharma belongs to the Medical - Biomedical and Genetics industry. This 548-stock industry is currently ranked #111. The industry has moved -7% year to date.
Amphastar Pharmaceuticals and Arbutus Biopharma could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Amphastar Pharmaceuticals (AMPH - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amphastar Pharmaceuticals is a member of our Medical group, which includes 1139 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Amphastar Pharmaceuticals is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AMPH's full-year earnings has moved 22.4% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, AMPH has returned 108.4% so far this year. Meanwhile, stocks in the Medical group have lost about 1.2% on average. This shows that Amphastar Pharmaceuticals is outperforming its peers so far this year.
Another stock in the Medical sector, Arbutus Biopharma (ABUS - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 6%.
For Arbutus Biopharma, the consensus EPS estimate for the current year has increased 22.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amphastar Pharmaceuticals belongs to the Medical - Generic Drugs industry, a group that includes 17 individual stocks and currently sits at #79 in the Zacks Industry Rank. On average, stocks in this group have gained 8.8% this year, meaning that AMPH is performing better in terms of year-to-date returns.
On the other hand, Arbutus Biopharma belongs to the Medical - Biomedical and Genetics industry. This 548-stock industry is currently ranked #111. The industry has moved -7% year to date.
Amphastar Pharmaceuticals and Arbutus Biopharma could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.